256 related articles for article (PubMed ID: 7295103)
1. Toxicity of middle molecules: clinical evaluation using a selective filtration artificial kidney.
Jörstad S; Smeby LC; Wideröe TE
Artif Organs; 1981; 4 Suppl():98-103. PubMed ID: 7295103
[TBL] [Abstract][Full Text] [Related]
2. Transport of uremic toxins through conventional hemodialysis membranes.
Jörstad S; Smeby LC; Wideröe TE; Berg KJ
Clin Nephrol; 1979 Oct; 12(4):168-73. PubMed ID: 509791
[TBL] [Abstract][Full Text] [Related]
3. Removal of uraemic toxins by haemofiltration with different membranes. The benefit of regenerating haemofiltrate using a newly developed system.
Jörstad S; Smeby LC; Wideröe TE; Berg KJ
Proc Eur Dial Transplant Assoc; 1979; 16():212-7. PubMed ID: 548983
[TBL] [Abstract][Full Text] [Related]
4. Transport of small, middle, and large molecular weight substances in a dual filtration artificial kidney.
Smeby LC; Jörstad S; Wideröe TE; Svartaas TM
Artif Organs; 1981; 4 Suppl():104-9. PubMed ID: 7295075
[TBL] [Abstract][Full Text] [Related]
5. The effect of hemodialysis on endogenous middle molecules in uremic patients.
Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
[TBL] [Abstract][Full Text] [Related]
6. Problems and solutions for artificial kidney.
Vanholder R
Technol Health Care; 2000; 8(6):373-9. PubMed ID: 11258583
[TBL] [Abstract][Full Text] [Related]
7. [Medium-sized molecules and the process of uremic intoxication].
Lutz W
Pol Tyg Lek; 1976 Jul; 31(27):1173-6. PubMed ID: 951302
[No Abstract] [Full Text] [Related]
8. Plasma middle molecules in asymptomatic and "sick" uremic patients.
Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxic properties of plasma fractions from uremic patients.
Delaporte C; Gros F; Jonsson C; Bergström J
Artif Organs; 1981; 4 Suppl():68-70. PubMed ID: 7295099
[TBL] [Abstract][Full Text] [Related]
10. Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment.
Válek A; Dzúrik R; Spustová V; Válková D
Artif Organs; 1981; 4 Suppl():173-6. PubMed ID: 7295088
[TBL] [Abstract][Full Text] [Related]
11. Removal of uremic toxins and regeneration of hemofiltrate by a selective dual hemofiltration artificial kidney (SEDUFARK) system.
Jørstad S; Smeby LC; Widerøe TE; Berg KJ
Clin Nephrol; 1980 Feb; 13(2):85-92. PubMed ID: 6988123
[TBL] [Abstract][Full Text] [Related]
12. Blood levels of middle molecules and their effects on motor nerve conduction velocity.
Botella J; Gea T; Sanz-Guajardo D; Criado M; Torres MT; Guardiola J
Artif Organs; 1981; 4 Suppl():151-5. PubMed ID: 7295082
[TBL] [Abstract][Full Text] [Related]
13. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
Lustenberger N; Schindhelm K; Nordmeyer C; Schurek HJ; Stolte H
Artif Organs; 1981; 4 Suppl():110-4. PubMed ID: 7295076
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. [Short-term dialyses using the Rhodial system].
Lichtenberg R
Z Urol Nephrol; 1978 Jul; 71(7):433-43. PubMed ID: 696018
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and metabolic consequences of uremic toxicity].
Rutkowski P
Przegl Lek; 2006; 63(4):209-17. PubMed ID: 17080744
[TBL] [Abstract][Full Text] [Related]
17. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
Maduell F
Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of uremic middle molecules in regular hemodialysis patients.
Asaba H; Alvestrand A; Fürst P; Bergström J
Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
[TBL] [Abstract][Full Text] [Related]
19. [Renal replacement therapy by hemodialysis: an overview].
Jacobs C
Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the clearance and generation rate of endogenous peptides in normal subjects and uremic patients.
Peters JH; Gotch FA; Keen M; Berridge BJ; Chao WR
Trans Am Soc Artif Intern Organs; 1974; 20 B():417-23. PubMed ID: 4450293
[No Abstract] [Full Text] [Related]
[Next] [New Search]
